MK-677, also called ibutamoren, is an orally active non-peptide compound that prompts the body to release its own growth hormone by mimicking ghrelin at the growth hormone secretagogue receptor, and the honest bottom line is that its pharmacology is well-characterized while its clinical value is not. It was advanced through formal pharmaceutical development across several decades for growth hormone deficiency, frailty, muscle wasting, and bone loss, yet it has never been approved for any indication, and it sits today in an unapproved research-chemical space that is not legally sold for human consumption and is prohibited in competitive sport. The literature consistently shows it raises growth hormone and the downstream marker IGF-1, while the open questions cluster around raised blood sugar, reduced insulin sensitivity, fluid retention, and the unknowns of chronically elevated IGF-1.
MK-677 reliably raises growth hormone and IGF-1 through oral ghrelin-receptor activation, but after decades of study it holds no regulatory approval for any indication and is sold only as a Research Use Only compound, not for human use.
What separates MK-677 from the injectable peptides it gets grouped with is chemistry, not just convenience. It is a small-molecule, non-peptide ghrelin mimetic that survives oral dosing, where peptide secretagogues degrade in the gut and require subcutaneous injection. The published mechanism is an amplification of the body's own pathway rather than a hormone supplied from outside, which is the root of both its appeal and its unsettled safety questions.
Published studies describe MK-677 as relatively selective for the growth hormone axis, raising growth hormone and IGF-1 with little sustained effect on cortisol, though it can modestly affect prolactin in some people.
The effects attributed to MK-677 trace back to the rise in growth hormone and IGF-1 it produces, and the evidence behind them is uneven enough that separating the documented from the anecdotal matters. The best-supported finding from controlled studies is an increase in lean body mass, while the most reliable and immediate effect, a pronounced rise in appetite, follows directly from the compound's ghrelin-mimicking action.
The effects with the most support are increased lean mass, heightened appetite, and altered sleep architecture, while the broader anti-aging and recovery claims remain unproven in controlled research.
The side effects follow directly from what the compound does to the growth hormone axis, and several are reported consistently enough in the literature to count as expected rather than rare. The most clinically important is metabolic: by raising growth hormone, MK-677 reduces insulin sensitivity and can raise fasting blood sugar and hemoglobin A1c, a meaningful concern for anyone with prediabetes, diabetes, or metabolic risk. Because the compound is unapproved, none of these effects are managed under formal medical supervision in typical use, which compounds them.
The congestive heart failure signal from a hip-fracture trial in frail older adults, combined with reduced insulin sensitivity and raised hemoglobin A1c, marks heart failure, diabetes, active or prior cancer, and pregnancy as the clearest avoid categories.
MK-677 carries a longer and more substantial clinical record than most compounds sold in the same gray market, because it was advanced through formal pharmaceutical development before approval was abandoned. Human trials reliably confirm the mechanism: the compound raises growth hormone and IGF-1 to levels comparable with younger adults. What the same body of research repeatedly found is the gap between that hormonal effect and the functional outcomes that approval would require.
The two-year trial record validates that MK-677 sustains elevated growth hormone, IGF-1, and lean body mass, but the absence of functional benefit combined with the blood-glucose and congestive heart failure signals is why it remains unapproved after decades of study.
Because MK-677 is not an approved medicine, there is no official dosing guideline, and the figures that circulate come from clinical study protocols and anecdotal use rather than a regulator-sanctioned label. The literature describes oral administration as the compound's defining convenience, with a half-life of several hours that lets a single daily dose hold growth hormone and IGF-1 elevated across the day and night. The absence of a validated dosing standard is itself a documented limitation, since individual responses to appetite, fluid retention, and glucose vary widely.
Doses referenced in non-clinical use fall around ten to twenty-five milligrams taken orally once daily, but every one of these patterns sits outside formal medical guidance, and no regulator-sanctioned dosing label exists.
MK-677 sits in a legally ambiguous space that the published record frames as a warning rather than a loophole. It has not been approved by the FDA or comparable regulators for any indication, so it cannot be legally marketed or sold as a drug or as a dietary supplement for human consumption. In practice it is sold as a research chemical labeled for laboratory or research use only, a convention that lets sellers operate while placing the compound outside the consumer-protection framework that governs approved medicines and supplements.
| Dimension | Status |
|---|---|
| FDA approval | None, for any indication |
| Sale channel | Research chemical, labeled not for human use |
| Controlled-substance scheduling | Generally unscheduled in the United States |
| Competitive sport | Prohibited at all times by WADA (hormones and growth factors) |
MK-677 holds no FDA approval and is sold only as a Research Use Only chemical, and it is prohibited at all times in sport by the World Anti-Doping Agency under the category covering hormones and growth factors.
MK-677 is usually set against two different things: the injectable peptide secretagogues and injectable growth hormone itself. Against peptides such as ipamorelin, the GHRP family, and CJC-1295, the documented difference is delivery and duration, since those peptides are amino-acid chains that degrade in the digestive tract and require subcutaneous injection. Against injectable growth hormone, the compound works upstream, prompting the body's own pulses rather than supplying the hormone directly, which preserves the feedback loop but produces a milder, less controllable effect.
| Criteria | MK-677 | Injectable peptide secretagogues | Injectable growth hormone |
|---|---|---|---|
| Delivery | Oral, once daily | Subcutaneous injection | Subcutaneous injection |
| Action | Upstream, natural pulses | Upstream, shorter-acting | Direct hormone supply |
| Blood-sugar effect | Stronger | Often milder | Variable |
| Appetite and fluid | Pronounced | More targeted | Less pronounced |
MK-677's oral convenience and sustained IGF-1 elevation come at the cost of stronger appetite stimulation, fluid retention, and blood-sugar effects than many injectable peptide options, and all of these compounds share unapproved status for the uses in question.
The published record on the research-chemical market is blunt: it is unregulated, so the burden of verifying what is in a product falls entirely on the buyer. Pricing runs relatively low compared with prescription hormone therapy, but low cost is documented as a possible marker of underdosing or substitution rather than a sign of quality. No government body checks identity, purity, or label accuracy, and independent testing in this category has repeatedly found products that are underdosed, contaminated, or contain a different compound than advertised.
Because no government body checks identity, purity, or label accuracy, independent testing in this category has repeatedly found underdosed, contaminated, or misidentified products, making the uncertainty about what is actually in the vial a permanent part of the risk, separate from the molecule's pharmacology.
The long-term picture is where the gaps in evidence matter most, since even the longest studies leave key questions open. Continued use sustains elevated growth hormone and IGF-1 rather than letting them drift back down, and the available multi-year data suggest the hormonal effect does not simply fade, though feedback systems may blunt the response over time. The clearest ongoing concern documented in the literature is metabolic, because the compound persistently lowers insulin sensitivity and can raise fasting glucose and A1c.
Across multi-year data the durability of benefit reads as modest and uncertain while the metabolic cost accumulates through persistently lowered insulin sensitivity and raised A1c, which is precisely the balance that kept the compound from approval.
Educational use only. This article describes what the published scientific and clinical literature reports about MK-677. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
